Search

Your search keyword '"Schneider, Christof"' showing total 755 results

Search Constraints

Start Over You searched for: Author "Schneider, Christof" Remove constraint Author: "Schneider, Christof"
755 results on '"Schneider, Christof"'

Search Results

1. Higher TIER bumble bees and solitary bees recommendations for a semi-field experimental design

2. Evaluation of honey bee larvae data: sensitivity to PPPs and impact analysis of EFSA Bee GD

3. Correlation of Structural and Magnetic Properties of RFeO3 (R=Dy, Lu)

4. Summary of an ICPPR Non-Apis workshop – Subgroup higher tier (bumble bees and solitary bees) with recommendations for a semi-field experimental design

7. Report of the activities of the ICPPR Bee Brood Working Group

8. Progress on the Osmia acute oral test - findings of the ICPPR Non-Apis subgroup solitary bee laboratory testing

13. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

14. Role of Dy on the magnetic properties of orthorhombic DyFeO3

15. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

16. Molecular map of chronic lymphocytic leukemia and its impact on outcome

17. Terahertz displacive excitation of a coherent Raman-active phonon in V$_2$O$_3$

18. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

19. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

20. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

21. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

22. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

23. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

24. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis

25. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

26. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

28. Strain-engineering of the charge and spin-orbital interactions in Sr2IrO4

29. Proximity-Induced Odd-Frequency Superconductivity in a Topological Insulator

31. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

32. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

33. Electronic Localization in CaVO3 Films via Bandwidth Control

35. Relationship between crystal structure and multiferroic orders in orthorhombic perovskite manganites

36. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

37. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

38. Single-axis dependent structural and multiferroic properties of orthorhombic RMnO$_3$ (R = Gd - Lu)

39. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

40. Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry.

43. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling

44. Tuning the multiferroic mechanisms of TbMnO3 by epitaxial strain

45. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

46. Electron-phonon Coupling and the Superconducting Phase Diagram of the LaAlO3-SrTiO3 Interface

47. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

49. Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia

50. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Catalog

Books, media, physical & digital resources